JP6063628B2 - ５−アザシチジンを用いる、非小細胞肺癌の治療方法 - Google Patents

５−アザシチジンを用いる、非小細胞肺癌の治療方法 Download PDF

Info

Publication number
JP6063628B2
JP6063628B2 JP2011549167A JP2011549167A JP6063628B2 JP 6063628 B2 JP6063628 B2 JP 6063628B2 JP 2011549167 A JP2011549167 A JP 2011549167A JP 2011549167 A JP2011549167 A JP 2011549167A JP 6063628 B2 JP6063628 B2 JP 6063628B2
Authority
JP
Japan
Prior art keywords
azacytidine
cells
nsclc
cell
aza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011549167A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012517427A (ja
JP2012517427A5 (OSRAM
Inventor
エヌ． ングエン アアロン
エヌ． ングエン アアロン
ジェイ． マクベトフ クイルエ
ジェイ． マクベトフ クイルエ
Original Assignee
セルジーン インターナショナル サルル
セルジーン インターナショナル サルル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セルジーン インターナショナル サルル, セルジーン インターナショナル サルル filed Critical セルジーン インターナショナル サルル
Publication of JP2012517427A publication Critical patent/JP2012517427A/ja
Publication of JP2012517427A5 publication Critical patent/JP2012517427A5/ja
Application granted granted Critical
Publication of JP6063628B2 publication Critical patent/JP6063628B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011549167A 2009-02-10 2010-02-09 ５−アザシチジンを用いる、非小細胞肺癌の治療方法 Active JP6063628B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15147909P 2009-02-10 2009-02-10
US61/151,479 2009-02-10
PCT/US2010/000361 WO2010093435A1 (en) 2009-02-10 2010-02-09 Methods for treating non-small cell lung cancer using 5-azacytidine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015032530A Division JP2015131822A (ja) 2009-02-10 2015-02-23 ５−アザシチジンを用いる、非小細胞肺癌の治療方法

Publications (3)

Publication Number Publication Date
JP2012517427A JP2012517427A (ja) 2012-08-02
JP2012517427A5 JP2012517427A5 (OSRAM) 2013-03-21
JP6063628B2 true JP6063628B2 (ja) 2017-01-18

Family

ID=42115561

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011549167A Active JP6063628B2 (ja) 2009-02-10 2010-02-09 ５−アザシチジンを用いる、非小細胞肺癌の治療方法
JP2015032530A Pending JP2015131822A (ja) 2009-02-10 2015-02-23 ５−アザシチジンを用いる、非小細胞肺癌の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015032530A Pending JP2015131822A (ja) 2009-02-10 2015-02-23 ５−アザシチジンを用いる、非小細胞肺癌の治療方法

Country Status (5)

Country Link
US (2) US8492361B2 (OSRAM)
EP (1) EP2396007A1 (OSRAM)
JP (2) JP6063628B2 (OSRAM)
CA (1) CA2789365A1 (OSRAM)
WO (1) WO2010093435A1 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6063628B2 (ja) 2009-02-10 2017-01-18 セルジーン インターナショナル サルル ５−アザシチジンを用いる、非小細胞肺癌の治療方法
WO2013022872A1 (en) 2011-08-10 2013-02-14 Celgene Corporation Gene methylation biomarkers and methods of use thereof
EP2760456A1 (en) 2011-09-26 2014-08-06 Celgene Corporation Combination therapy for chemoresistant cancers
EP2773322A1 (en) 2011-11-01 2014-09-10 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs
KR102064626B1 (ko) * 2012-02-24 2020-01-09 시그날 파마소티칼 엘엘씨 Tor 키나제 억제자 복합 치료법을 사용한 비소세포 폐암의 치료 방법
NZ631082A (en) * 2013-04-17 2017-06-30 Signal Pharm Llc Methods for treating cancer using tor kinase inhibitor combination therapy
WO2014180996A1 (en) * 2013-05-10 2014-11-13 Embl Use of 5-azacytidine to inhibit nonsense-mediated rna decay (nmd)
SG11201608303QA (en) 2014-04-04 2016-11-29 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
WO2015160882A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
WO2015160868A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc Methods for treating cancer using tor kinase inhibitor combination therapy
WO2015195786A2 (en) * 2014-06-17 2015-12-23 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs
CN106604745A (zh) * 2014-09-08 2017-04-26 细胞基因公司 使用胞苷类似物的口服制剂与抗pd1或抗pdl1单克隆抗体的组合治疗疾病或病症的方法
US9801983B2 (en) 2014-12-18 2017-10-31 Cook Medical Technologies Llc Medical devices for delivering a bioactive to a point of treatment and methods of making medical devices
WO2016201337A1 (en) * 2015-06-12 2016-12-15 Immungene, Inc. Engineered antibody-interferon fusion molecules for the treatment of glucose-regulated protein 94 (grp94) expressing cancers
BR112018011324A2 (pt) 2015-12-03 2018-12-04 Epidestiny Inc ?composições contendo decitabina, 5azacitidina e tetra-hidrouridina e usos das mesmas?
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection
CA3090291C (en) * 2018-02-07 2023-10-17 Lovelace Biomedical Research Institute Inhalable dry powder cytidine analogue composition and method of use as a treatment for cancer
KR102785135B1 (ko) 2018-06-11 2025-03-21 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 눈 질환을 치료하는 탈메틸화

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
WO2009058394A1 (en) 2007-11-01 2009-05-07 Celgene Corporation Cytidine analogs for treatment of myelodysplastic syndromes
SI2695609T1 (sl) * 2008-05-15 2020-03-31 Celgene Corporation Oral formulacije anologov citidina in postopki za njihovo uporabo
JP6063628B2 (ja) 2009-02-10 2017-01-18 セルジーン インターナショナル サルル ５−アザシチジンを用いる、非小細胞肺癌の治療方法
WO2013022872A1 (en) 2011-08-10 2013-02-14 Celgene Corporation Gene methylation biomarkers and methods of use thereof

Also Published As

Publication number Publication date
JP2015131822A (ja) 2015-07-23
EP2396007A1 (en) 2011-12-21
WO2010093435A1 (en) 2010-08-19
US20130274219A1 (en) 2013-10-17
JP2012517427A (ja) 2012-08-02
US8492361B2 (en) 2013-07-23
CA2789365A1 (en) 2010-08-19
US8841277B2 (en) 2014-09-23
US20110319355A1 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
JP6063628B2 (ja) ５−アザシチジンを用いる、非小細胞肺癌の治療方法
JP6162709B2 (ja) シチジンアナログの経口製剤を使用して癌を治療する方法
KR101633134B1 (ko) 시티딘 유사체의 경구 제형 및 그의 사용 방법
JP2015212268A (ja) 併用療法を用いた治療方法
WO2013022872A1 (en) Gene methylation biomarkers and methods of use thereof
AU2012316266B2 (en) Combination therapy for chemoresistant cancers
AU2012312308B2 (en) Romidepsin and 5-azacitidine for use in treating lymphoma
US20140357567A1 (en) Methods for treating cancers using oral formulations of cytidine analogs
WO2025188680A1 (en) Use of plk1 inhibitor in combination of gemcitabine or carboplatin in treating ovarian carcinoma
WO2015195786A2 (en) Methods for treating cancers using oral formulations of cytidine analogs
NZ624323B2 (en) Methods for treating cancers using oral formulations of cytidine analogs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140428

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140731

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160603

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161006

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161219

R150 Certificate of patent or registration of utility model

Ref document number: 6063628

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250